Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
A. Villalba
Observed name:
A Villalba
Institutions:
Hospital Universitario La Paz,
Hospital La Paz Institute for Health Research
Observed institutions:
Hospital Universitario La Paz,
Hospital La Paz Institute for Health Research
ORCID:
0000-0002-9798-0265
Observed ORCID:
0000-0002-9798-0265
OpenAlex ID:
A5015862898
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab
2013
·
Ch Plasencia
, D Pascual-Salcedo
, et al.
·
Annals of the Rheumatic Diseases
·
10
FRI0186 Concomitant csdmards influence clinical response to tnf inhibitors only in overweight patients with axial spondyloarthritis
2018
·
B. Hernández-Breijo
, V. Navarro-Compán
, et al.
·
Annals of the Rheumatic Diseases
·
4
PDF
THU0189 Therapeutic Drug Monitoring (TDM) in Rheumatic Day Clinic Enables to Reduce Pharmaceutical Cost Maintaining Clinical Efficacy
2013
·
D. Pascual-Salcedo
, C. Plasencia
, et al.
·
Annals of the Rheumatic Diseases
·
4
AB0573 The immunogenicity of biological therapies correlates with clinical efficacy in psoriatic arthritis (psa) in long-term treatment with infliximab and adalimumab.
2013
·
D. Cajigas
, C. Plasencia
, et al.
·
Annals of the Rheumatic Diseases
·
4
SAT0084 Anti-carbamylated protein antibodies as potential biomarkers of disease activity in early arthritis patients
2018
·
A. Gonzalez
, C. Regueiro
, et al.
·
Annals of the Rheumatic Diseases
·
2
PDF
SAT0141 Optimal circulating adalimumab levels range associated with good clinical response in rheumatoid arthritis patients
2017
·
A Jochems
, A Martinez-Feito
, et al.
·
Annals of the Rheumatic Diseases
·
2
PDF
FRI0138 Comparison of Golimumab Levels Detected by Two Different Enzyme-Linked Immunosorbent Assays: Promonitor VS Sanquin
2015
·
T. Jurado
, C. Plasencia
, et al.
·
Annals of the Rheumatic Diseases
·
2
THU0171 Influence of Immunogenicity of Anti-TNF Therapy in RA Patients with a Long-Term Treatment with Infliximab or Adalimumab
2013
·
A. Villalba
, C. Plasencia
, et al.
·
Annals of the Rheumatic Diseases
·
2
THU0219 The Infliximab Dose Increase is Not Correlated with Clinical Improvement in RA Patients
2013
·
M.T. López-Casla
, D. Pascual-Salcedo
, et al.
·
Annals of the Rheumatic Diseases
·
2
Abs1004 Unraveling the Influence of Rheumatoid Factor on Ra Treatment Success
2025
·
M. Juárez
, S. Salas
, et al.
·
Annals of the Rheumatic Diseases
·
1
Ab0897 Predictive Models to Forecast Difficult-to-manage Axial Spondyloarthritis
2024
·
M. Juárez
, D. Benavent
, et al.
·
Annals of the Rheumatic Diseases
·
1
Pos0676 the Challenge of Identifying Difficult-to-treat Axial Spondyloarthritis in Clinical Practice: Results From La Paz-spa Cohort
2023
·
M. Juárez
, D. Benavent
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Op0204 Circulating Cd4+cxcr5+pd-1hi Follicular Helper T Cells Are Elevated in Patients With Rheumatoid Arthritis and Predict Treatment Response to Abatacept or Tnf Blockers
2023
·
I. Monjo
, B. Nieto-Carvalhal
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Ab0029 Circulating Cd39+ Treg Cells in Early Rheumatoid Arthritis Facilitate the Antiinflammatory Action of Methotrexate and Serve as Early Biomarkers of Clinical Response
2022
·
A. Villalba
, L. Nuño
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis
2021
·
A Martínez-Feito
, V Navarro-Compán
, et al.
·
Scandinavian Journal of Rheumatology
·
1
SAT0168 Discontinuation of first biologic therapy in rheumatoid arthritis: main causes and correlation between secondary inefficacy and development of immunogenicity
2017
·
P Bogas
, C Plasencia
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
FRI0062 Synovial fluid treg cells secrete il-17 and at the same time are potent suppressors of tresp cell proliferation, tnf alpha and ifn gamma production
2017
·
M Benito-Miguel
, A Villalba
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
FRI0204 Comparison the long-term clinical outcomes between nontnf-inhibitors versus tnf-i in ra patients who failed to a first tnf-i
2017
·
P Bogas
, C Plasencia
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
FRI0405 Extraarticular Manifestations in Patients with Spondyloarthritis under Biologic Treatment
2016
·
A. Pieren
, D. Peiteado
, et al.
·
Annals of the Rheumatic Diseases
·
1
THU0157 Comparison of Clinical Outcomes between Rheumatoid Arthritis Patients under TNF Inhibitors Using A Tapering Strategy or Standard Therapy Regimen in Daily Clinical Practice
2014
·
C. Plasencia
, G. Wolbink
, et al.
·
Annals of the Rheumatic Diseases
·
1
OP0253 The Early Infliximab Levels Monitoring Can Predict the Developement of Anti-Drug Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
2014
·
P.-R. Chamaida
, D. Pascual-Salcedo
, et al.
·
Annals of the Rheumatic Diseases
·
1
THU0216 Down-Titration and Discontinuation of Infliximab, Adalimumab and Etanercept in Established Rheumatoid Arthritis
2013
·
L. Lojo
, G. Bonilla
, et al.
·
Annals of the Rheumatic Diseases
·
1
THU0282 Clinical efficacy to a second anti-tnf therapy is associated with the development of antibodies against the first anti-TNF therapy in patients with spondyloartrhitis
2012
·
S. García Carazo
, C. Plasencia
, et al.
·
Annals of the Rheumatic Diseases
·
1
ABS0576 Safety and effectiveness of the use of combined therapy with bDMARDS and tsDMARDs in inmune-mediated inflammatory diseases
2025
·
N. López-Juanes
, C. Ureta
, et al.
·
Annals of the Rheumatic Diseases
Abs0947 the Impact of Cancer on the Management of Rheumatoid Arthritis: Insights From the Arca Registry
2025
·
J. Molina-Collada
, C. Plasencia-Rodríguez
, et al.
·
Annals of the Rheumatic Diseases
Show more works
View as search
Works count:
62
Citation count:
46
H-index:
4
I10-index:
1
Year
Topic
Type